$BP

Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More

Wall Street analysts issued updates on various companies. BP (NYSE: BP) was upgraded to Overweight with a $71 target, Dollar Tree (NASDAQ: DLTR) to Buy with a $140 target, and Occidental Petroleum (NYSE: OXY) to Buy with a $69 target. Exxon Mobil (NYSE: XOM) was downgraded to Equal Weight with an $182 target. Other notable initiations and changes include Lennar (NYSE: LEN), Rocket Lab (NASDAQ: RKLB), Teva Pharmaceuticals (NASDAQ: TEVA), and more.

Original reporting
Published Oct 1, 2026, 12:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More — source image
Decision brief

The 30-second read

$BPBullishLow
01

Why it matters

Rating changes provide fresh guidance for each stock, but the overall market narrative is dominated by macro data and bond yields.

02

Market read

While the rating updates are new, they are routine and offer modest trading ideas; broader market moves are driven by macro data.

03

What to watch

Potential macro backdrop from inflation data and bond yields could dominate price action despite rating changes.

Relevance 5/10Novelty 4/10Timing: today

Background

The article aggregates analyst upgrades, downgrades, and initiations released on Thursday, October 1, 2026.

Company-level read

Ticker impact

$BPBullishMedium confidence
Context

BP upgraded to Overweight from Equal Weight with price target raised to $71.

Expected impact

likely upside as investors price in higher target

Evidence & confidence

Morgan Stanley's upgrade signals improved outlook.

$DLTRBullishMedium confidence
Context

Dollar Tree upgraded to Buy from Hold with price target raised to $140.

Expected impact

potential upside from new buy rating

Evidence & confidence

Loop Capital's upgrade reflects stronger expectations.

$OXYBullishMedium confidence
Context

Occidental Petroleum upgraded to Buy from Neutral with target $69.

Expected impact

likely upward pressure

Evidence & confidence

Goldman Sachs sees better prospects.

$TRPBullishMedium confidence
Context

TC Energy upgraded to Buy from Neutral with target $71.

Expected impact

potential upside

Evidence & confidence

Goldman Sachs raises outlook.

$UTHRBullishMedium confidence
Context

United Therapeutics upgraded to Buy from Neutral with target $728.

Expected impact

likely upside

Evidence & confidence

BTIG's rating change signals confidence.

$CBNKBearishMedium confidence
Context

Capital Bancorp downgraded to Market Perform from Outperform, target unchanged at $42.

Expected impact

potential downside pressure

Evidence & confidence

Hovde Group reduces outlook.

$LIFEBearishMedium confidence
Context

Ethos Technologies downgraded to Neutral from Overweight, target $37.

Expected impact

likely downside

Evidence & confidence

JPMorgan lowers expectations.

$XOMBearishMedium confidence
Context

Exxon Mobil downgraded to Equal Weight from Overweight, target $182.

Expected impact

potential downside

Evidence & confidence

Wells Fargo reduces rating.

Market effects

Broad analyst rating changes may shift sector sentiment for energy, retail, biotech, and housing.

US market participants may adjust positions in the listed stocks today.

Limited to US-listed equities; no direct global macro impact.

Counterpoint

Some investors may view the upgrades as already priced in and focus on the downgrades for short ideas.

Key entities

  • Morgan Stanley

    Provided upgrades for BP and initiated coverage of Lennar.

  • Goldman Sachs

    Upgraded Occidental Petroleum, TC Energy, and United Therapeutics.

Related articles

$RKLBMed

RKLB Stock’s 2-Week Rally Is On The Line — But Cathie Wood’s ARK Is Loading Up As Wall Street Sees 55% Upside

Rocket Lab (RKLB) shares are down 5% this week, despite a 1% rise on Thursday. Cathie Wood's ARK funds bought $16.5M in RKLB shares. Analysts average a 'Strong Buy' rating with a $109.15 price target, implying 55% upside. Citi initiated coverage with a 'Buy' rating and $105 target. RKLB secured a 20-launch contract with Synspective, its largest commercial deal.

$TEVALow

Teva's Degevma Wins FDA Approval, Joining a Crowded Field of Xgeva Biosimilars for Cancer That Reaches Bone

Teva Pharmaceuticals' Degevma, a biosimilar to Amgen's Xgeva, received FDA approval for preventing bone complications in cancer patients. Teva aims to launch Degevma and its companion product, Ponlimsi, in the U.S. soon, with pricing and insurance coverage details pending. The approval adds to the growing list of Xgeva biosimilars, potentially increasing treatment options and lowering costs for patients.

$BPMed

HSBC upgrades BP and TotalEnergies shares to buy — CNBC

HSBC upgraded BP and TotalEnergies to 'buy' due to higher European natural gas prices, with a 34% and 40% price forecast increase for 2023 and 2024, respectively. Analyst Kim Fustier expects improved forecasts for their oil businesses and refining margins, potential cash generation, and share buybacks. JPMorgan also upgraded BP to 'overweight', citing business simplification and growth prospects, including a significant discovery in Brazil.

$ORAMed

Why Ormat Technologies Stock Is Powering Down Today

Ormat Technologies (ORA) shares fell 2% on October 1, following a 10.3% drop in September. UBS downgraded the stock to neutral and lowered its price target to $100, citing reduced 2028 EBITDA guidance. Ormat expects 2028 revenue of $1.225B-$1.275B and EBITDA of $750M-$800M, down from 2025 figures of $990M and $582M, respectively.